secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2026-08-12T20:07:37+00:00
Accession:  0001104659-26-094869
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent reports H1 results and licenses ARR-002 to Allist for up to $80.6M
---------------------------------------------------------------------------

- Entered exclusive license with Allist for ARR-002 in Greater China; potential $80.6M in upfront, milestones, plus tiered royalties (mid-single to low-double digit).
- Cash and investments $373.1M at June 30, 2026; expected to fund operations into 2028.
- Net loss $93.2M for H1 2026 vs $95.8M in H1 2025; R&D $80.0M, G&A $18.8M.
- Firmonertinib Phase 3 FURVENT topline data for EGFR exon20 NSCLC expected 2H 2026.
- ARR-002 first patient dosing expected Q3 2026; ARR-217 advanced to Phase 1b dose optimization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/0001104659-26-094869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer